DRUG
Firmagon
120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
Status
Completed
Phase
Phase 2
Enrollment
57
Locations
6
Results
Not posted
Publications
0
Study summary
Evaluation of the interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treatment
The identification of lesions responsible for biological recurrence or persistent biological disease in patients with prostatic adenocarcinoma (PA) remains an outstanding problem due to the lack of sensitivity of standard imaging techniques. The efficacy of empirical radiation therapy of the prostate + pelvis zone in only half of patients with increased PSA suggests an underestimation of lesions. PET-68Ga-PSMA or PET-PSMA technique showed a clear gain in sensitivity for the detection of lesions in this context compared to PET-Choline which was already more sensitive than standard imaging. It is about 50% for a PSA \<0.5 ng / ml vs 20% for a PSA \<1 ng / ml for TEP-Choline technique. However, the indication of empirical radiotherapy is raised when the PSA exceeds 0.2 ng / ml. It is therefore still necessary to increase the sensitivity of PET-PSMA. A flare-up-related effect was observed in a small animal experiment and in a patient after androgen blocking treatment, inducing a sharp increase in the intensity of previously visualized lesions and the appearance of 13 new lesions. It would therefore be possible to increase the expression of PSMA by the lesions at the origin of the biological recurrence of AP and thus to improve their detection by PET-PSMA after potentiation by short-term androgen blocking by an antagonist of LH-RH.
Interventions
DRUG
120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
Timeline
First posted
May 18, 2020
Study start
Sep 14, 2020
Primary completion
May 2, 2023
Study completion
Apr 3, 2024
Results posted
Not reported
Registry updated
Aug 14, 2025
Outcomes
Comparison of the proportion of patients presenting a positive PET during the initial PSMA-PET (prior to androgenic blockade) and the PSMA-H-PET (PSMA PET after androgenic blockade), patient being his own witness
Time frame · Day 14 after the androgenic blockade
PSMA-PET
Evaluation of the reproductibility of the PSMA-PET and PSMA-H-PET interpretation
Time frame · Day 14 after the androgenic blockade
PSMA-PET and PSMA-H-PET
Evaluation of the impact of androgenic blockade on lesions revealed by PSMA-H PET in comparison with the initial PSMA-PET
Time frame · Day 14 after the androgenic blockade
Number of lesions (PSMA-ET and PSMA-H PET)
Evaluation of the impact of androgenic blockade on lesions revealed by PSMA-H PET in comparison with the initial PSMA-PET
Time frame · Day 14 after the androgenic blockade
Fixation intensity (PSMA-ET and PSMA-H PET)
Evaluation of the PSMA-PET and PSMA-H PET impact in the therapeutic management modifications
Time frame · Day 14 after the androgenic blockade
Comparison between treatments planned after PSMA-PET and treatments planned after PSMA-H-PET
Evaluation of the interest of late pelvic acquisition 3 hours after the PSMA-68Ga injection
Time frame · Day 14 after the androgenic blockade
PSMA-PET and PSMA-H-PET efficience
Evaluation of the results correlation of each PSMA-PET with clinical data, histologic primary tumor and biologic data of the recurrence (PSA kinetic and velocity assessed at screening)
Time frame · Day 14 after the androgenic blockade
PSMA-PET efficience
Evaluation of the results correlation of each PSMA-PET with clinical data, histologic primary tumor and biologic data of the recurrence (PSA kinetic and velocity assessed at screening)
Time frame · Day 14 after the androgenic blockade
PSA rate
Evaluation of the correlation between the PSA and testosterone rates variations between D0 and D14 and the PSMA-PET results
Time frame · Day 14 after the androgenic blockade
PSA and testosterone rates and PSMA-PET results
Tolerance profile
Time frame · Up to Day 15-30 visit
Incidence of PSMA-H-PET Adverse Events assessed by the Common Terminology Criteria for Adverse Events (CTCAE version 5.0)
Eligibility
Inclusion Criteria: * Age ≥ 18 years old; * Hormone-naive patients, initially treated curatively by prostatectomy for prostate adenocarcinoma and having a first or new biological recurrence (PSA greater than 0.2 ng/ml; confirmed on at least two successive dosages in the last 12 months) OR Hormone-naive patients, initially treated curatively by external radiotherapy or by brachytherapy for prostate adenocarcinoma and having a biological recurrence (PSA Nadir + 2ng/ml ; confirmed on at least two successive dosages in the last 12 months ) OR hormone-naive patients treated by surgery or external radiotherapy or brachytherapy for prostate adenocarcinoma but with persistent biological disease (PSA detectable after prostatectomy, or unchanged or increasing PSA after external radiotherapy or brachytherapy); * Diagnostic recurrence assessment by any information or examination carried out since the ascension of the PSA, not having revealed local recurrence or lymph node lesions which may benefit from to external radiation * Signed informed consent. Exclusion Criteria: * Patient already treated by hormonotherapy; * Formal contraindication to hormonotherapy; * Formal contraindication to external radiotherapy * Formal contraindication to the Lasilix administration during the PET exams: Hypersensitivity to Furosemide or to one of the excipients, functional acute renal insufficiency, hepatic encephalopathy, urinary tracts obstruction, hypovolemia or dehydration, severe hypokalemia, severe hyponatremia, hepatitis in evolution and severe hepatocellular insufficiency in haemodialysis patient and patient presenting a severe renal insufficiency (creatinine clearance \<30 ml / min) due to the risk of accumulation of furosemide, which is then mainly eliminated by the biliary route; * Significant cardiovascular affection such as myocardial infarction within the last 6 months preceding inclusion, severe rhythm disturbances, stroke within 6 months prior to inclusion, prolonged corrected QT interval with QTc \> 450 msecs according to Bazett formula; * Impossibility to comply with the study follow-up for geographical or psychic reasons. * Patient under protection of justice (Under tutorship, curatorship or deprived of liberty)
Study locations
France. Showing up to 24 locations stored in the fast local snapshot.
Chu Gabriel Montpied
Clermont-Ferrand, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Hospitalier de Grenoble Hôpital Nord Michallon
La Tronche, France
Centre Léon Bérard
Lyon, France
APHM - Hôpital Nord
Marseille, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Memorial Sloan Kettering Cancer Center · Prostate Cancer · Prostatic Adenocarcinoma
Not applicable
Completed
41
2026-07
Novartis · Metastatic Neuroendocrine Prostate Cancer
Phase 1
Active, not recruiting
31
2026-07
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
M.D. Anderson Cancer Center · Prostate Cancer
Phase 1 / Phase 2
Recruiting
6
2026-07
NYU Langone Health · Intraprostatic Prostate Cancer
Not applicable
Recruiting
28
2026-07
Memorial Sloan Kettering Cancer Center · Metastatic Castration Sensitive Prostate Cancer
Phase 2
Completed
16
2026-07
Stanford University · Prostate Adenocarcinoma · Stage I Prostate Cancer
Not applicable
Completed
146
2026-07
University of Wisconsin, Madison · Prostate Cancer
Phase 1 / Phase 2
Active, not recruiting
57
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.